NII to develop antibody-based therapy for COVID-19

The Department of Biotechnology’s National Institute of Immunology (NII) in Delhi is going to procure coronavirus and blood samples from recovered patients. According to Dr. Amulya Panda, Director, NII, the samples from recovered patients will help in analysing the antibody quality in the blood with an aim to develop an antibody-based therapy. According to Dr Panda, studies are also underway on the spike protein of the novel coronavirus to develop a vaccine. Scientist at NII will utilize their previous expertise of vaccine development. They have previously developed an immunomodulator for leprosy and are well equipped, from the laboratory to animal house and to the product development cell, to take a vaccine candidate from the laboratory to industry.